Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Status:
Completed
Trial end date:
2020-07-28
Target enrollment:
Participant gender:
Summary
In an attempt to reduce relapse risk and improve outcomes following haploidentical
transplantation for patients with high risk hematologic malignancies, the investigators will
implement several strategies to augment the well documented effect of NK cell alloreactivity
seen in HLA-mismatched transplantation. These strategies include (1) choosing potential
haploidentical donors for optimal NK-alloreactivity, (2) utilizing proteasome inhibition
post-transplant with MLN9708 to both sensitize tumor cells to NK cytotoxicity and protect
against graft-versus-host disease (GVHD), and (3) eliminating mycophenolate mofetil from the
post-transplant immunosuppression regimen to improve NK cell reconstitution following
haploidentical peripheral blood stem cell transplantation.